Cargando…

Therapeutic Targeting of Fibrotic Epithelial-Mesenchymal Transition–An Outstanding Challenge

Back in 1995, a landmark paper was published, which shaped the fibrosis literature for many years to come. During the characterization of a fibroblast-specific marker (FSP1) in the kidneys, an observation was made, which gave rise to the hypothesis that “fibroblasts in some cases arise from the loca...

Descripción completa

Detalles Bibliográficos
Autores principales: Fintha, Attila, Gasparics, Ákos, Rosivall, László, Sebe, Attila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6482168/
https://www.ncbi.nlm.nih.gov/pubmed/31057405
http://dx.doi.org/10.3389/fphar.2019.00388
_version_ 1783413836497289216
author Fintha, Attila
Gasparics, Ákos
Rosivall, László
Sebe, Attila
author_facet Fintha, Attila
Gasparics, Ákos
Rosivall, László
Sebe, Attila
author_sort Fintha, Attila
collection PubMed
description Back in 1995, a landmark paper was published, which shaped the fibrosis literature for many years to come. During the characterization of a fibroblast-specific marker (FSP1) in the kidneys, an observation was made, which gave rise to the hypothesis that “fibroblasts in some cases arise from the local conversion of epithelium.” In the following years, epithelial-mesenchymal transition was in the spotlight of fibrosis research, especially in the kidney. However, the hypothesis came under scrutiny following some discouraging findings from lineage tracing experiments and clinical observations. In this review, we provide a timely overview of the current position of the epithelial-mesenchymal transition hypothesis in the context of fibrosis (with a certain focus on renal fibrosis) and highlight some of the potential hurdles and pitfalls preventing therapeutic breakthroughs targeting fibrotic epithelial-mesenchymal transition.
format Online
Article
Text
id pubmed-6482168
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-64821682019-05-03 Therapeutic Targeting of Fibrotic Epithelial-Mesenchymal Transition–An Outstanding Challenge Fintha, Attila Gasparics, Ákos Rosivall, László Sebe, Attila Front Pharmacol Pharmacology Back in 1995, a landmark paper was published, which shaped the fibrosis literature for many years to come. During the characterization of a fibroblast-specific marker (FSP1) in the kidneys, an observation was made, which gave rise to the hypothesis that “fibroblasts in some cases arise from the local conversion of epithelium.” In the following years, epithelial-mesenchymal transition was in the spotlight of fibrosis research, especially in the kidney. However, the hypothesis came under scrutiny following some discouraging findings from lineage tracing experiments and clinical observations. In this review, we provide a timely overview of the current position of the epithelial-mesenchymal transition hypothesis in the context of fibrosis (with a certain focus on renal fibrosis) and highlight some of the potential hurdles and pitfalls preventing therapeutic breakthroughs targeting fibrotic epithelial-mesenchymal transition. Frontiers Media S.A. 2019-04-18 /pmc/articles/PMC6482168/ /pubmed/31057405 http://dx.doi.org/10.3389/fphar.2019.00388 Text en Copyright © 2019 Fintha, Gasparics, Rosivall and Sebe. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Fintha, Attila
Gasparics, Ákos
Rosivall, László
Sebe, Attila
Therapeutic Targeting of Fibrotic Epithelial-Mesenchymal Transition–An Outstanding Challenge
title Therapeutic Targeting of Fibrotic Epithelial-Mesenchymal Transition–An Outstanding Challenge
title_full Therapeutic Targeting of Fibrotic Epithelial-Mesenchymal Transition–An Outstanding Challenge
title_fullStr Therapeutic Targeting of Fibrotic Epithelial-Mesenchymal Transition–An Outstanding Challenge
title_full_unstemmed Therapeutic Targeting of Fibrotic Epithelial-Mesenchymal Transition–An Outstanding Challenge
title_short Therapeutic Targeting of Fibrotic Epithelial-Mesenchymal Transition–An Outstanding Challenge
title_sort therapeutic targeting of fibrotic epithelial-mesenchymal transition–an outstanding challenge
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6482168/
https://www.ncbi.nlm.nih.gov/pubmed/31057405
http://dx.doi.org/10.3389/fphar.2019.00388
work_keys_str_mv AT finthaattila therapeutictargetingoffibroticepithelialmesenchymaltransitionanoutstandingchallenge
AT gasparicsakos therapeutictargetingoffibroticepithelialmesenchymaltransitionanoutstandingchallenge
AT rosivalllaszlo therapeutictargetingoffibroticepithelialmesenchymaltransitionanoutstandingchallenge
AT sebeattila therapeutictargetingoffibroticepithelialmesenchymaltransitionanoutstandingchallenge